Metabolic Disease News and Research

RSS

Early childhood presents short-lived window for intervention to ensure future cardio-metabolic health

Research conducted at LSU Health New Orleans School of Public Health has found that exposure to poverty does not produce metabolic and inflammatory biomarkers in young, healthy children. It identifies early childhood as an opportunity to prevent a known association in adults between poverty and the metabolic syndrome. The study is one of the first to characterize the timing of exposure to such stress and the emergence of the physiologic changes leading to cardio-metabolic disease and to document these relationships during this critical developmental period.

10 Mar 2016

Low level of physical fitness in early life associated with Type 2 Diabetes risk in adulthood

The combination of low aerobic capacity and low muscle strength at age 18 is associated with a three times greater risk of developing Type 2 Diabetes in adulthood, according to new research from the Icahn School of Medicine at Mount Sinai published online today in the journal Annals of Internal Medicine.

8 Mar 2016

New method could help scientists conduct in-depth research on malignant tumors in cancer patients

Scientists at the Children's Medical Center Research Institute at UT Southwestern have pioneered a new method for conducting in-depth research on malignant tumors in patients, in the process discovering new complexities underlying cancer biology and overturning a nearly century-old perception about cancer metabolism.

5 Feb 2016

New way to more efficiently deliver CRISPR/Cas9 therapeutic to mice with Tyrosinemia type I

University of Massachusetts Medical School researchers have found a way to more efficiently delivery a CRISPR/Cas9 therapeutic to adult mice with the metabolic disease Tyrosinemia type I that may also prove to be safer for use in humans.

2 Feb 2016

Sedentary behavior associated with poor cardiovascular health, diabetes in people with severe obesity

Sedentary behavior is associated with poor cardiovascular health and diabetes in adults with severe obesity, independent of how much exercise they perform, a University of Pittsburgh Graduate School of Public Health-led study showed for the first time.

13 Jan 2016

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

Rani Therapeutics announced today that it has entered into a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, to evaluate Rani's novel oral drug delivery platform. The companies have agreed to conduct feasibility studies over the next two years, in which Rani will test select biologic molecules in the area of metabolic disease to evaluate the oral delivery of these molecules.

6 Jan 2016

Researchers discover methods for reducing age-related stem cell dysfunction, metabolic disease in aged mice

Mayo Clinic researchers have taken what they hope will be the first step toward preventing and reversing age-related stem cell dysfunction and metabolic disease. That includes diabetes, which affects 12.2 million Americans age 60 and older, according to the National Council on Aging.

5 Jan 2016

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

A new study by researchers from Harvard T.H. Chan School of Public Health and colleagues describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.

24 Dec 2015

TSRI scientists use new drug discovery technique to identify anti-diabetes compound

Scientists from The Scripps Research Institute have deployed a powerful new drug discovery technique to identify an anti-diabetes compound with a novel mechanism of action.

8 Dec 2015

Heptares announces strategic drug discovery collaboration with Pfizer

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, announces that it has entered into a strategic drug discovery collaboration with Pfizer Inc. to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas.

30 Nov 2015

Potential treatment strategy for glycogen storage disease

Researchers from the Duke-NUS Graduate Medical School Singapore and Duke Medicine have identified a potential treatment strategy for an often-fatal inherited glycogen storage disease.

18 Nov 2015

Australian researchers define key characteristics of metabolically healthy obese

Australian researchers have defined some key characteristics of the metabolically healthy obese -- those obese individuals who remain free from type 2 diabetes and other disorders that usually associate with obesity. Their findings have implications for the treatment of type 2 diabetes, insulin resistance and obesity.

10 Nov 2015

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).

3 Nov 2015

Just one junk food snack is enough to trigger signs of metabolic disease

We hate to ruin Thanksgiving, but a new report appearing in the Nov. 2015 issue of The FASEB Journal suggests that for some people, overindulgence at the dinner table or at snack time is enough to trigger signs of metabolic disease.

3 Nov 2015

Diet missing soluble fiber promotes inflammation in the intestines, leading to weight gain

Eating too much high-fat, high-calorie food is considered the primary cause of obesity and obesity-related disease, including diabetes. While the excess calories consumed are a direct cause of the fat accumulation, scientists suspect that low-grade inflammation due to an altered gut microbiome may also be involved.

30 Oct 2015

Transition Therapeutics Ireland signs agreement for investigator-led TT701 Phase 2 clinical study

Transition Therapeutics Inc. announced today that Transition Therapeutics Ireland Limited has entered into an agreement for an investigator-led clinical study of drug candidate, TT701, with Brigham and Women's Hospital.

30 Oct 2015

Strensiq approved for treatment of patients with juvenile-onset HPP

Today, the U.S. Food and Drug Administration approved Strensiq (asfotase alfa) as the first approved treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP).

24 Oct 2015

Inflammatory response could be key link between dietary fats and obesity-related diseases

An enhanced inflammatory response could be the key link between high saturated fat intake - a recognized risk factor for obesity-related disorders - and the development of diseases like type 2 diabetes and atherosclerosis.

26 Sep 2015

AMRA, Pfizer collaborate to assess fat and muscle measurements to predict obesity, diabetes

AMRA announced that they have entered into a unique international collaboration with Pfizer Inc. to investigate the relationship between fat and muscle distribution in the body and metabolic health, including risk factors for conditions such as obesity and diabetes.

8 Sep 2015

Inhalation exposure to PM2.5 pollution triggers liver fibrosis

A research team led by Kezhong Zhang, Ph.D., at the Wayne State University School of Medicine's Center for Molecular Medicine and Genetics, has discovered that exposure to air pollution has a direct adverse health effect on the liver and causes liver fibrosis, an illness associated with metabolic disease and liver cancer.

3 Sep 2015